Should all acutely ill medical patients be treated with antithrombotic drugs? A review of the interventional trials

Thrombosis and Haemostasis

Volumn 109, Issue 4, 2013, Pages 589-595

  Violi, Francesco ^a   Perri, Ludovica ^a   Loffredo, Lorenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anticoagulants; Medical patients; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

AUTOPSY; COMPUTER ASSISTED TOMOGRAPHY; DEATH; ECHOGRAPHY; HEART FAILURE; HUMAN; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG SCINTISCANNING; OUTCOME ASSESSMENT; PHLEBOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RISK; SEVERE ACUTE RESPIRATORY SYNDROME; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; FIBRINOLYTIC AGENTS; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84875957160     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-11-0860     Document Type: Review

References (28)

1. Anderson FA, Jr., Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Int Med 1991; 151: 933-938.
2. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Int Med 2002; 162: 1245-1248.
3. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Int Med 2000; 160: 3415-3420.
4. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16: 159-164.
5. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
6. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Resp Crit Care Med 2000; 161: 1109-1114.
7. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
8. Lederle FA, Sacks JM, Fiore L, et al. The prophylaxis of medical patients for thromboembolism pilot study. Am J Med 2006; 119: 54-59.
9. Kakkar AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2011; 365: 2463-2472.
10. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Int Med 2010; 153: 8-18.
11. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J 2006; 332: 325-329.
12. Mahe I, Bergmann JF, d'Azemar P, et al. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study. Eur J Clin Pharmacol 2005; 61: 347-351.
13. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 381S-3453S.
14. Wittkowsky AK. Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. Am J Manag Care 2004; 10 (10 Suppl): S297-306; discussion S12-17.
15. Ageno W. Do medical patients need to receive pharmacologic prophylaxis for the prevention of venous thromboembolism? Intern Emerg Med 2012; 7 (Suppl 3): S189-192.
16. Khoury H, Welner S, Kubin M, et al. Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilisation of preventive therapies. Thromb Haemost 2011; 106: 600-608.
17. Albertsen IE, Larsen TB, Rasmussen LH, et al. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis. Drugs 2012; 72: 1755-1764.
18. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-660.
19. Oger E, Bressollette L, Nonent M, et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost 2002; 88: 592-597.
20. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336: 251-257.
21. Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol 2001; 54: 810-816.
22. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Resp Crit Care Med 1994; 149: 818-824.
23. Smeeth L, Cook C, Thomas S, et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006; 367: 1075-1079.
24. Levi M, Keller TT, van Gorp E, et al. Infection and inflammation and the coagulation system. Cardiovasc Res 2003; 60: 26-39.
25. Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. Nature Rev Microbiol 2006; 4: 445-457.
26. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164: 963-968.
27. Lawall H, Matthiessen A, Hohmann V, et al. Venous thromboembolism in medical outpatients-a cross-sectional survey of risk assessment and prophylaxis. Thromb Haemost 2011; 105: 190-196.
28. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e195S-226S.